Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Management of Menorrhagia


Published on


Published in: Health & Medicine
  • My personal experience with research paper writing services was highly positive. I sent a request to ⇒ ⇐ and found a writer within a few minutes. Because I had to move house and I literally didn’t have any time to sit on a computer for many hours every evening. Thankfully, the writer I chose followed my instructions to the letter. I know we can all write essays ourselves. For those in the same situation I was in, I recommend ⇒ ⇐.
    Are you sure you want to  Yes  No
    Your message goes here
  • Discover How to Cure uterine fibroids and PCOS At Any Age, Even If You’ve Tried Everything And Nothing Has Ever Worked For You Before ●●●
    Are you sure you want to  Yes  No
    Your message goes here
  • how to download??
    Are you sure you want to  Yes  No
    Your message goes here

Management of Menorrhagia

  1. 1. Management of Menorrhagia (Heavy Menstrual Bleeding) Dr Tan Yiap Loong Obstetric and Gynaecology Department Sarawak General Hospital
  2. 2. Definition <ul><li>Heavy menstrual bleeding (menorrhagia) is diagnosed when menstrual blood loss is considered excessive by the woman, interferes with women’s physical, social emotional, and/or quality of life </li></ul><ul><li>Highly subjective and personal issue </li></ul>
  3. 3. Definition <ul><li>In research studies- between 60 ml and 80 ml per menstruation </li></ul><ul><ul><li>not practical in the clinical setting </li></ul></ul><ul><li>Accompanied by other symptoms, such as menstrual pain (dysmenorrhoea) </li></ul>
  4. 4. How common is it? <ul><li>Between 4% and 51.6% </li></ul>
  5. 5. Normal Menstrual Cycle <ul><li>Cycle length </li></ul><ul><ul><li>average 29 days </li></ul></ul><ul><ul><li>Range 23 - 39 days </li></ul></ul><ul><li>Duration of flow </li></ul><ul><ul><li>Average 4 days </li></ul></ul><ul><ul><li>3 to 7 days </li></ul></ul><ul><li>Amount </li></ul><ul><ul><li>Average 35 mls </li></ul></ul><ul><li>Quality </li></ul><ul><ul><li>Non-clotting blood, endometrial debris </li></ul></ul>
  6. 6. Previously…………. <ul><li>In the early 1990s it was estimated that at least 60% of women presenting with HMB would have a hysterectomy to treat the problem, often as a first line. </li></ul><ul><li>Emotive procedure </li></ul><ul><ul><li>womb and fertility often seen as being part of a woman ’ s identity </li></ul></ul><ul><ul><li>undesirable for some people </li></ul></ul>
  7. 7. Now…………. <ul><li>Things have changed and the number of hysterectomies is decreasing rapidly. </li></ul><ul><li>In the UK, aim to be managed by primary health care </li></ul><ul><li>Nevertheless, clinically, hysterectomy is associated with a very high satisfaction rate by those who have undergone the operation </li></ul>
  8. 8. Risk Factors <ul><li>While HMB may occur in the presence of histological abnormality, the association does not necessarily imply causality </li></ul><ul><li>Uterine fibroids (30%) </li></ul><ul><ul><li>epidemiological study in the UK found that site, size and number of fibroids are linked to the level of MBL </li></ul></ul><ul><ul><li>(Sulaiman S, Khaund A, McMillan N, et al. 2004) </li></ul></ul>
  9. 9. Risk Factors <ul><li>Age </li></ul><ul><ul><li>? an increase in MBL with age </li></ul></ul><ul><li>Polyps </li></ul><ul><ul><li>No studies linked the presence of uterine polyps with HMB. </li></ul></ul><ul><li>Blood disorders </li></ul><ul><ul><li>von Willebrand disease (vWD) </li></ul></ul><ul><ul><ul><li>13.0-15.4% in women with menorrhagia compared with the general population </li></ul></ul></ul><ul><ul><ul><li>(Woo YL, White B, Corbally R, et al. 2002) </li></ul></ul></ul>
  10. 10. Risk Factors <ul><li>Thyroid disorders </li></ul><ul><li>Endometriosis/ Adenomyosis </li></ul><ul><ul><li>usually dysmenorrhoea but two studies have found that HMB may be a significant secondary symptom </li></ul></ul><ul><li>Racial groups </li></ul><ul><li>Lifestyle </li></ul><ul><ul><li>observational studies showed impact on MBL </li></ul></ul>
  11. 11. Risk Factors <ul><li>Uterine Pathology? </li></ul><ul><ul><li>Results of 20 observational and diagnostic studies show that the majority of women with HMB have no histological abnormality that can be implicated in causing HMB </li></ul></ul><ul><ul><li>Rare for a woman who has presented with HMB and has undergone investigations to have an underlying pre-malignant or malignant condition </li></ul></ul><ul><ul><li>RCOG </li></ul></ul><ul><ul><ul><li>women aged between 35 and 54 years, eight of every 10,000 women who presented with HMB in primary care would have endometrial carcinoma. </li></ul></ul></ul>
  12. 12. Risk Factors <ul><li>Dysfunctional uterine bleeding </li></ul><ul><ul><li>No organic cause </li></ul></ul><ul><ul><li>Frequently due to anovulation </li></ul></ul><ul><li>Others </li></ul><ul><ul><li>PID </li></ul></ul><ul><ul><li>Malignancy </li></ul></ul><ul><ul><li>IUCD </li></ul></ul><ul><ul><li>Medications (Tamoxifen, Unapposed oestrogen treatment) </li></ul></ul>
  13. 13. What is our goal? <ul><li>Heavy menstrual bleeding (HMB) should be recognised as having a major impact on a woman ’ s quality of life, and any intervention should aim to improve this rather than focusing on menstrual blood loss. [C] </li></ul><ul><li>(NICE 2007) </li></ul>
  14. 14. How should I assess a woman with menorrhagia?
  15. 15. History and Physical Examination <ul><li>Nature of the bleeding (flooding, clots, double padding,etc) and related symptoms (anaemia) </li></ul><ul><li>Directed to identify potential pathology </li></ul><ul><li>Explore women’s prespective, ideas, concerns </li></ul><ul><li>Previous treatments </li></ul>
  16. 16. History and Physical Examination <ul><li>Physical examination if an abnormality is suspected (e.g. if there is intermenstrual or postcoital bleeding, or pelvic pain or pressure) </li></ul><ul><ul><li>Recommended before all ; </li></ul></ul><ul><ul><ul><ul><li>LNG-IUS fittings </li></ul></ul></ul></ul><ul><ul><ul><ul><li>investigations for structural abnormalities </li></ul></ul></ul></ul><ul><ul><ul><ul><li>investigations for histological abnormalities </li></ul></ul></ul></ul>
  17. 17. History and Physical Examination <ul><li>Measurement of MBL </li></ul><ul><ul><li>Direct- alkaline haematin </li></ul></ul><ul><ul><ul><li>Accurate and precise </li></ul></ul></ul><ul><ul><ul><li>Impractical </li></ul></ul></ul><ul><ul><ul><li>Little impact on management </li></ul></ul></ul><ul><ul><li>Indirect- Pictorial Blood Loss Assessment Chart (PBAC) </li></ul></ul><ul><ul><ul><li>Highly variable </li></ul></ul></ul><ul><ul><li>NOT RECOMMENDED ROUTINELY </li></ul></ul><ul><ul><li>SHOULD BE DETERMINED BY PATIENT HERSELF </li></ul></ul>
  18. 18. Investigations (Laboratory) <ul><li>FBC test - in all women with HMB </li></ul><ul><li>Coagulation profile -if HMB since menarche/ family history </li></ul><ul><li>Serum Ferritin - not routinely </li></ul><ul><li>Hormone testing - not recommended </li></ul><ul><li>Thyroid function test - when signs and symptoms present </li></ul>
  19. 19. Investigations (Structural and Histological) <ul><li>Ultrasound </li></ul><ul><ul><li>sensitivity 48 - 100% </li></ul></ul><ul><ul><li>specificity 12 - 100% </li></ul></ul><ul><ul><li>better at identifying fibroids than hysteroscopy </li></ul></ul><ul><ul><li>less accurate for identifying polyps or endometrial disease </li></ul></ul><ul><ul><li>should be undertaken in the following circumstances: </li></ul></ul><ul><ul><ul><li>uterus is palpable abdominally </li></ul></ul></ul><ul><ul><ul><li>vaginal examination reveals a pelvic mass of uncertain origin </li></ul></ul></ul><ul><ul><ul><li>pharmaceutical treatment fails </li></ul></ul></ul><ul><li>Hysteroscopy </li></ul><ul><ul><li>when ultrasound results are inconclusive </li></ul></ul><ul><ul><li>to determine the exact location of a fibroid or the exact nature of the abnormality </li></ul></ul>
  20. 20. Investigations (Structural and Histological) <ul><li>Magnetic resonance imaging (MRI) </li></ul><ul><li>Dilatation and curettage </li></ul><ul><ul><li>alone should not be used as a diagnostic tool </li></ul></ul><ul><li>Endometrial biopsy </li></ul><ul><ul><li>persistent intermenstrual bleeding </li></ul></ul><ul><ul><li>in women aged 45 and over </li></ul></ul><ul><ul><li>treatment failure or ineffective treatment </li></ul></ul>
  21. 21. What advice and counselling should I give to a woman with menorrhagia?
  22. 22. Discuss……. <ul><li>Natural variability and range of menstrual blood loss and reassure the woman (if appropriate) </li></ul><ul><li>Different treatment options </li></ul><ul><ul><li>acceptability </li></ul></ul><ul><ul><li>effectiveness of treatments </li></ul></ul><ul><ul><li>adverse effects </li></ul></ul><ul><ul><li>contraception </li></ul></ul><ul><ul><li>implications of treatment on fertility </li></ul></ul>
  23. 23. Give…….. <ul><li>The opportunity to review and agree any treatment decision. </li></ul><ul><li>Adequate time and support from healthcare professionals in the decision-making process </li></ul>
  24. 24. When should I prescribe pharmaceutical treatment in women presenting with menorrhagia?
  25. 25. Drug Treatment <ul><li>Pharmaceutical treatment (recommended first-line) </li></ul><ul><ul><li>no symptoms or signs suggestive of underlying pathology (structural or histological uterine abnormalities </li></ul></ul><ul><ul><li>are awaiting the results of investigations </li></ul></ul>
  26. 26. Drug Treatment <ul><li>If either hormonal or non-hormonal treatments are acceptable (descending order) </li></ul><ul><ul><li>levonorgestrel-releasing intrauterine system (Mirena®) provided long-term (at least 12-months) use is anticipated </li></ul></ul><ul><ul><li>tranexamic acid or non-steroidal anti-inflammatory drugs (NSAIDs) or combined oral contraceptives </li></ul></ul><ul><ul><li>norethisterone (15 mg) daily from days 5 to 26 of the menstrual cycle, or injected long-acting progestogens ( Depo-Provera®) . </li></ul></ul>
  27. 27. Drug Treatment <ul><li>Levonorgestrel-releasing intrauterine system (Mirena®) </li></ul><ul><ul><li>RCTs reduction between 71% and 96% </li></ul></ul><ul><ul><li>Full benefit of treatment may not be seen for 6 months </li></ul></ul><ul><ul><li>30% amenorrhoea </li></ul></ul><ul><ul><li>RCT (ECLIPSE) </li></ul></ul><ul><ul><ul><li>LNG-IUS vs other pharmaceutical treatments </li></ul></ul></ul>
  28. 28. Drug Treatment <ul><li>Tranexamic acid </li></ul><ul><ul><li>1 g (2 X 500 mg tablets) three to four times daily, from the onset of bleeding for up to 4 days </li></ul></ul><ul><ul><li>reductions in MBL (29% to 58%) </li></ul></ul><ul><li>NSAIDs (mefenamic acid or naproxen) </li></ul><ul><ul><li>reductions in MBL (20% to 49%) </li></ul></ul><ul><ul><li>dysmenorrhoea </li></ul></ul>
  29. 29. Drug Treatment <ul><li>COCs </li></ul><ul><ul><li>reduction of MBL of 43% </li></ul></ul><ul><li>Oral progestogen </li></ul><ul><ul><li>used long-term reduces MBL by 83% </li></ul></ul><ul><li>Etonogestrel implant (Implanon ® ) </li></ul><ul><ul><li>no licence for the treatment of HMB </li></ul></ul><ul><li>Depot medroxyprogesterone acetate (DMPA) </li></ul><ul><ul><li>No evidence </li></ul></ul><ul><ul><li>Amenorrhea is a side effect (NICE) </li></ul></ul>
  30. 30. Drug Treatment <ul><li>If hormonal treatments are not acceptable to the woman, then either tranexamic acid or NSAIDs can be used </li></ul><ul><li>GnRH analogue </li></ul><ul><ul><li>prior to surgery </li></ul></ul><ul><ul><li>other treatment options for uterine fibroids, including surgery or uterine artery embolisation (UAE), are contraindicated </li></ul></ul><ul><ul><li>‘ add-back ’ therapy </li></ul></ul><ul><ul><li>amenorrhea rates of 89% </li></ul></ul>
  31. 31. What should I do if initial drug treatment is ineffective in a woman with menorrhagia? <ul><li>A second pharmaceutical treatment </li></ul><ul><li>Add on another drug rather than immediate referral to surgery. </li></ul><ul><li>Use of NSAIDs and/or tranexamic acid should be stopped if it does not improve symptoms within three menstrual cycles </li></ul>
  32. 32. How can I rapidly stop heavy bleeding, if necessary? <ul><li>Oral norethisterone, 5 mg three times daily (licensed use) or, in very severe cases, 10 mg three times daily (unlicensed use), then tapering down to 5 mg three times daily for a further week </li></ul>
  33. 33. Not Recommended <ul><li>Oral progestogens in the luteal phase only </li></ul><ul><li>Danazol (side effects) </li></ul><ul><li>Etamsylate </li></ul>
  34. 34. When should I refer? <ul><li>Malignancy is suspected </li></ul><ul><ul><li>refer urgently (within 2 weeks) </li></ul></ul><ul><li>Significant negative impact on her quality of life despite adequate trials of pharmaceutical treatment </li></ul><ul><li>Anaemia - not improved despite treatment (other causes excluded) </li></ul><ul><ul><li>make a routine referral. </li></ul></ul><ul><li>Wants to consider surgical options </li></ul>
  35. 35. Surgical Treatment <ul><li>Used as the initial treatment for HMB? </li></ul><ul><ul><li>Unclear </li></ul></ul><ul><ul><li>Endometrial ablation may be offered </li></ul></ul><ul><ul><li>Hysterectomy should not be used as a first-line treatment solely for HMB </li></ul></ul><ul><li>Whether a pharmaceutical intervention should always be tried first? </li></ul>
  36. 36. Surgical Treatment <ul><li>Non-hysterectomy or interventional radiology </li></ul><ul><li>Hysterectomy </li></ul>
  37. 37. Non-hysterectomy or interventional radiology <ul><li>Endometrial ablation </li></ul><ul><ul><li>1st generation (TCRE, Rollerball) </li></ul></ul><ul><ul><li>2nd generation (MEA, Inpedence-controlled bipolar radiofrequency, balloon thermal) </li></ul></ul><ul><ul><li>Affects fertility </li></ul></ul><ul><ul><li>Use of effective contraception following procedure </li></ul></ul><ul><ul><li>50% amenorrhoea, 95% satisfaction rate </li></ul></ul>
  38. 38. Non-hysterectomy or interventional radiology <ul><li>Uterine artery embolisation (UAE) </li></ul><ul><ul><li>Fertility is potentially retained </li></ul></ul>
  39. 39. Non-hysterectomy or interventional radiology <ul><li>Hysteroscopic myomectomy </li></ul><ul><li>Myomectomy </li></ul>
  40. 40. Hysterectomy <ul><li>Fibroids >3cm + severe impact on QoL </li></ul><ul><li>Desire for amenorrhoea </li></ul><ul><li>Other treatments failed, contraindicated, declined </li></ul><ul><li>No desire to retain uterus or fertility </li></ul><ul><li>Fully informed women request it </li></ul>
  41. 41. Hysterectomy <ul><li>Route </li></ul><ul><ul><li>First line : Vaginal </li></ul></ul><ul><ul><li>Second line : Abdominal </li></ul></ul><ul><li>Ovaries may also be removed </li></ul><ul><li>100% amenorrhoea </li></ul><ul><li>95% satisfaction rate </li></ul>
  42. 43. Many Thanks
  43. 44. Referrences <ul><li>Sulaiman S, Khaund A, McMillan N, et al. Uterine fibroids - do size and location determine menstrual blood loss? European Journal of Obstetrics and Gynecology 2004;115(1):85 - 9 </li></ul><ul><li>Woo YL, White B, Corbally R, et al. Von Willebrand ’ s disease: an important cause of dysfunctional uterine bleeding. Blood Coagulation and Fibrinolysis 2002;13(2):89 - 93 </li></ul>